Showing results (771-780 of 1,649) with videos related to
Sort By:
Pageof 165
Therapeutic Innovation & Regulatory Science|June 19, 2023
Benchmarking Patient Engagement Capabilities and Preparedness of Drug Development SponsorsJennifer Y Kim, Maria Paula Bautista Acelas, Courtney A Granville, et al.Therapeutic Innovation & Regulatory Science|June 30, 2023
Preventability of Adverse Drug Reactions Related to Antibiotics: An Assessment Based on Spontaneous Reporting SystemHa N Tran, Tien N T Nguyen, Ngan T K Tran, et al.Therapeutic Innovation & Regulatory Science|March 10, 2026
Ethical Challenges and Considerations in Decentralized Clinical Trials (DCTs): Insights from a Scoping ReviewLijia Han, Kai Hong Ooi, Krisna Veni Balakrishnan, et al.Therapeutic Innovation & Regulatory Science|March 15, 2026
Research on the Quality Evaluation Indicators of Real-World Data in the Review of Anti-Tumor Drugs for Chinese Regulatory FrameworksJie-Ying Zhang, Yong Tang, Fang-Zheng Dong, et al.Therapeutic Innovation & Regulatory Science|March 5, 2026
Diving into the Regulatory Landscape of Digital TherapeuticsMadhumitha Masilamani, Melvin GeorgeTherapeutic Innovation & Regulatory Science|March 5, 2026
Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontiersYanmei Rao, Li Dong, Zhe HuangTherapeutic Innovation & Regulatory Science|March 16, 2026
Regulatory Approaches to Electronic Labelling in the USA, EU, and India: A Comparative OverviewKomal Saini, Ramandeep SinghTherapeutic Innovation & Regulatory Science|February 27, 2026
The UK's 2026 Clinical Trial Regulations: A Strategic Analysis for Global Pharmaceutical SponsorsAmer AlghabbanTherapeutic Innovation & Regulatory Science|March 12, 2026
Impurities in Oncology Pharmaceuticals: A Review of Classification, Detection Methods, Regulatory Frameworks and Emerging TrendsKishan Balehalli Shivananda, Nagarjun Somaprakash, Pradeep Kumar BadiyaTherapeutic Innovation & Regulatory Science|March 28, 2026
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric ModelsGloria Nnadwa AlhassanPageof 165